<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d349" origId="Atovaquone"><sentence id="DrugDDI.d349.s0" origId="s0" text="Atovaquone is highly bound to plasma protein (99.9%)."><entity charOffset="0-10" id="DrugDDI.d349.s0.e0" origId="s0.p0" text="Atovaquone" type="drug"/><entity charOffset="30-44" id="DrugDDI.d349.s0.e1" origId="s0.p4" text="plasma protein" type="drug"/><pair e1="DrugDDI.d349.s0.e0" e2="DrugDDI.d349.s0.e1" id="DrugDDI.d349.s0.p0" interaction="true"/></sentence><sentence id="DrugDDI.d349.s1" origId="s1" text="Therefore, caution should be used when administering MEPRON concurrently with other highly plasma protein- bound drugs with narrow therapeutic indices, as competition for binding sites may occur."><entity charOffset="53-59" id="DrugDDI.d349.s1.e0" origId="s1.p14" text="MEPRON" type="drug"/></sentence><sentence id="DrugDDI.d349.s2" origId="s2" text="The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone."><entity charOffset="14-28" id="DrugDDI.d349.s2.e0" origId="s2.p24" text="plasma protein" type="drug"/><entity charOffset="40-50" id="DrugDDI.d349.s2.e1" origId="s2.p25" text="atovaquone" type="drug"/><entity charOffset="54-66" id="DrugDDI.d349.s2.e2" origId="s2.p26" text="human plasma" type="drug"/><entity charOffset="132-141" id="DrugDDI.d349.s2.e3" origId="s2.p32" text="phenytoin" type="drug"/><entity charOffset="178-187" id="DrugDDI.d349.s2.e4" origId="s2.p41" text="phenytoin" type="drug"/><entity charOffset="216-226" id="DrugDDI.d349.s2.e5" origId="s2.p44" text="atovaquone" type="drug"/><pair e1="DrugDDI.d349.s2.e0" e2="DrugDDI.d349.s2.e1" id="DrugDDI.d349.s2.p0" interaction="false"/><pair e1="DrugDDI.d349.s2.e0" e2="DrugDDI.d349.s2.e2" id="DrugDDI.d349.s2.p1" interaction="false"/><pair e1="DrugDDI.d349.s2.e0" e2="DrugDDI.d349.s2.e3" id="DrugDDI.d349.s2.p2" interaction="false"/><pair e1="DrugDDI.d349.s2.e0" e2="DrugDDI.d349.s2.e4" id="DrugDDI.d349.s2.p3" interaction="false"/><pair e1="DrugDDI.d349.s2.e0" e2="DrugDDI.d349.s2.e5" id="DrugDDI.d349.s2.p4" interaction="false"/><pair e1="DrugDDI.d349.s2.e1" e2="DrugDDI.d349.s2.e2" id="DrugDDI.d349.s2.p5" interaction="false"/><pair e1="DrugDDI.d349.s2.e1" e2="DrugDDI.d349.s2.e3" id="DrugDDI.d349.s2.p6" interaction="false"/><pair e1="DrugDDI.d349.s2.e1" e2="DrugDDI.d349.s2.e4" id="DrugDDI.d349.s2.p7" interaction="false"/><pair e1="DrugDDI.d349.s2.e1" e2="DrugDDI.d349.s2.e5" id="DrugDDI.d349.s2.p8" interaction="false"/><pair e1="DrugDDI.d349.s2.e2" e2="DrugDDI.d349.s2.e3" id="DrugDDI.d349.s2.p9" interaction="false"/><pair e1="DrugDDI.d349.s2.e2" e2="DrugDDI.d349.s2.e4" id="DrugDDI.d349.s2.p10" interaction="false"/><pair e1="DrugDDI.d349.s2.e2" e2="DrugDDI.d349.s2.e5" id="DrugDDI.d349.s2.p11" interaction="false"/><pair e1="DrugDDI.d349.s2.e3" e2="DrugDDI.d349.s2.e4" id="DrugDDI.d349.s2.p12" interaction="false"/><pair e1="DrugDDI.d349.s2.e3" e2="DrugDDI.d349.s2.e5" id="DrugDDI.d349.s2.p13" interaction="false"/><pair e1="DrugDDI.d349.s2.e4" e2="DrugDDI.d349.s2.e5" id="DrugDDI.d349.s2.p14" interaction="false"/><negationtags>&lt;xcope&gt;The extent of plasma protein binding of atovaquone in human plasma is &lt;cue&gt;not&lt;/cue&gt; affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL),&lt;/xcope&gt; nor is the binding of phenytoin affected by the presence of atovaquone.</negationtags></sentence><sentence id="DrugDDI.d349.s3" origId="s3" text="Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations."><entity charOffset="0-8" id="DrugDDI.d349.s3.e0" origId="s3.p45" text="Rifampin" type="drug"/><entity charOffset="30-38" id="DrugDDI.d349.s3.e1" origId="s3.p48" text="rifampin" type="drug"/><entity charOffset="43-49" id="DrugDDI.d349.s3.e2" origId="s3.p50" text="MEPRON" type="drug"/><entity charOffset="127-137" id="DrugDDI.d349.s3.e3" origId="s3.p53" text="atovaquone" type="drug"/><pair e1="DrugDDI.d349.s3.e0" e2="DrugDDI.d349.s3.e1" id="DrugDDI.d349.s3.p0" interaction="false"/><pair e1="DrugDDI.d349.s3.e0" e2="DrugDDI.d349.s3.e2" id="DrugDDI.d349.s3.p1" interaction="false"/><pair e1="DrugDDI.d349.s3.e0" e2="DrugDDI.d349.s3.e3" id="DrugDDI.d349.s3.p2" interaction="false"/><pair e1="DrugDDI.d349.s3.e1" e2="DrugDDI.d349.s3.e2" id="DrugDDI.d349.s3.p3" interaction="true"/><pair e1="DrugDDI.d349.s3.e1" e2="DrugDDI.d349.s3.e3" id="DrugDDI.d349.s3.p4" interaction="false"/><pair e1="DrugDDI.d349.s3.e2" e2="DrugDDI.d349.s3.e3" id="DrugDDI.d349.s3.p5" interaction="false"/></sentence><sentence id="DrugDDI.d349.s4" origId="s4" text="Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON."><entity charOffset="16-24" id="DrugDDI.d349.s4.e0" origId="s4.p55" text="rifampin" type="drug"/><entity charOffset="86-92" id="DrugDDI.d349.s4.e1" origId="s4.p61" text="MEPRON" type="drug"/><pair e1="DrugDDI.d349.s4.e0" e2="DrugDDI.d349.s4.e1" id="DrugDDI.d349.s4.p0" interaction="true"/></sentence><sentence id="DrugDDI.d349.s5" origId="s5" text="Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin."><entity charOffset="0-9" id="DrugDDI.d349.s5.e0" origId="s5.p62" text="Rifabutin" type="drug"/><entity charOffset="19-28" id="DrugDDI.d349.s5.e1" origId="s5.p63" text="rifamycin" type="drug"/><entity charOffset="57-65" id="DrugDDI.d349.s5.e2" origId="s5.p66" text="rifampin" type="drug"/><entity charOffset="126-134" id="DrugDDI.d349.s5.e3" origId="s5.p73" text="rifampin" type="drug"/><pair e1="DrugDDI.d349.s5.e0" e2="DrugDDI.d349.s5.e1" id="DrugDDI.d349.s5.p0" interaction="false"/><pair e1="DrugDDI.d349.s5.e0" e2="DrugDDI.d349.s5.e2" id="DrugDDI.d349.s5.p1" interaction="false"/><pair e1="DrugDDI.d349.s5.e0" e2="DrugDDI.d349.s5.e3" id="DrugDDI.d349.s5.p2" interaction="false"/><pair e1="DrugDDI.d349.s5.e1" e2="DrugDDI.d349.s5.e2" id="DrugDDI.d349.s5.p3" interaction="false"/><pair e1="DrugDDI.d349.s5.e1" e2="DrugDDI.d349.s5.e3" id="DrugDDI.d349.s5.p4" interaction="false"/><pair e1="DrugDDI.d349.s5.e2" e2="DrugDDI.d349.s5.e3" id="DrugDDI.d349.s5.p5" interaction="false"/></sentence><sentence id="DrugDDI.d349.s6" origId="s6" text="No interaction trials have been conducted with MEPRON and rifabutin."><entity charOffset="47-53" id="DrugDDI.d349.s6.e0" origId="s6.p78" text="MEPRON" type="drug"/><entity charOffset="58-67" id="DrugDDI.d349.s6.e1" origId="s6.p80" text="rifabutin" type="drug"/><pair e1="DrugDDI.d349.s6.e0" e2="DrugDDI.d349.s6.e1" id="DrugDDI.d349.s6.p0" interaction="false"/><negationtags>&lt;xcope&gt;&lt;cue&gt;No&lt;/cue&gt; interaction trials have been conducted with MEPRON and rifabutin&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d349.s7" origId="s7" text="Drug/ Laboratory Test Interactions: It is not known if MEPRON interferes with clinical laboratory test or assay results."><entity charOffset="0-4" id="DrugDDI.d349.s7.e0" origId="s7.p81" text="Drug" type="drug"/><entity charOffset="55-61" id="DrugDDI.d349.s7.e1" origId="s7.p88" text="MEPRON" type="drug"/><pair e1="DrugDDI.d349.s7.e0" e2="DrugDDI.d349.s7.e1" id="DrugDDI.d349.s7.p0" interaction="false"/><negationtags>Drug/ Laboratory Test Interactions: &lt;xcope&gt; It is &lt;cue&gt;not&lt;/cue&gt; known if MEPRON interferes with clinical laboratory test or assay results&lt;/xcope&gt;.</negationtags></sentence></document>